Inventiva SACA

Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024

30 May 2024 01:30:00 By Nasdaq GlobeNewswire

Combined General Meeting of June 20, 2024 - Availability of the preparatory documents

30 May 2024 01:30:00 By Nasdaq GlobeNewswire

Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024

22 May 2024 15:00:00 By Nasdaq GlobeNewswire

Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update

21 May 2024 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH

16 May 2024 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor

13 May 2024 01:30:00 By Nasdaq GlobeNewswire

Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

03 Apr 2024 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces the nomination of Andre Turenne as Director

28 Mar 2024 02:00:00 By Nasdaq GlobeNewswire

Inventiva reports its 2023 full-year results

27 Mar 2024 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

22 Mar 2024 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

18 Mar 2024 15:00:00 By Nasdaq GlobeNewswire

Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D

13 Mar 2024 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed

07 Mar 2024 15:00:00 By Nasdaq GlobeNewswire

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

15 Feb 2024 15:35:00 By Nasdaq GlobeNewswire

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

24 Jan 2024 15:15:00 By Nasdaq GlobeNewswire

Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank

10 Jan 2024 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program

20 Dec 2023 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH

04 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

Inventiva reports 2023 Third Quarter Financial Information¹

21 Nov 2023 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023  

06 Nov 2023 15:00:00 By Nasdaq GlobeNewswire